U.S. Markets closed

Agenus begins enrollment in NCI-Sponsored randomized trial of Prophage G-200

Agenus announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 vaccine in combination with bevacizumab for treatment of recurrent glioblastoma multiforme in adult patients. The study is being sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute. The trial is expected to enroll 222 patients in treatment centers across the United States, and is the largest brain tumor vaccine trial ever funded by NCI and the largest vaccine study ever conducted with Avastin.